TABLE I.
Group | n | Treatment |
---|---|---|
I (experimental) | 5 | ADSC/LV-BMP-2 + HB Scaffold |
II (negative control) | 5 | ADSC/LV-GFP + HB Scaffold |
III (negative control) | 5 | Nontransduced ADSC + HB Scaffold |
IV (negative control) | 5 | HB Scaffold Alone |
Group | n | Treatment |
---|---|---|
I (experimental) | 5 | ADSC/LV-BMP-2 + HB Scaffold |
II (negative control) | 5 | ADSC/LV-GFP + HB Scaffold |
III (negative control) | 5 | Nontransduced ADSC + HB Scaffold |
IV (negative control) | 5 | HB Scaffold Alone |